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Background: With increased governmental interest in value assessment of technologies and where medical device
manufacturers are finding it increasingly necessary to become more familiar with economic evaluation methods,
the study sought to explore the levels of health economics knowledge within small and medium-sized enterprises
(SMEs) and to scope strategies they employ to demonstrate the value of their products to purchasers.
Methods: A short questionnaire was completed by participants attending one of five workshops on product
development in the medical device sector that took place in England between 2007 and 2011. From all responses
obtained, a large proportion of participants were based in SMEs (N = 43), and these responses were used for the
analysis. Statistical analysis using non-parametric tests was performed on questions with approximately interval
scales. Qualitative data from participant responses were analysed to reveal emerging themes.
Results: The questionnaire results revealed that 60% of SME participants (mostly company directors or managers,
including product or project managers) rated themselves as having low or no knowledge of health economics prior
to the workshops but the rest professed at least medium knowledge. Clinical trials and cost analyses or
cost-effectiveness studies were the most highly cited means by which SMEs aim to demonstrate value of products
to purchasers. Purchasers were perceived to place most importance on factors of safety, expert opinion,
cost-effectiveness and price. However many companies did not utilise formal decision-making tools to prioritise
these factors. There was no significant dependence of the use of decision-making tools in general with respect to
professed knowledge of health economics methods. SMEs did not state a preference for any particular aspect of
potential value when deciding whether to develop a product. A majority of SMEs stated they would use a health
economics tool. Research and development teams or marketing and sales departments would most likely use one.
Conclusion: This study points to the need for further research into the education requirements of SMEs in the area
of Health Technology Assessment (HTA) and also for investigation into how SMEs engage with existing HTA
processes as required by assessors such as NICE.* Correspondence: michael.craven@nottingham.ac.uk
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There has been an increasing focus on economics to an-
swer questions around efficiency and value for money in
healthcare [1]. For the medical device sector, this focus
has permeated through an increasing reliance on Health
Technology Assessment (HTA) to ensure that the intro-
duction of a new drug, medical device, or procedure is
cost effective in line with static or shrinking health bud-
gets in Europe and elsewhere [2]. For the medical device
sector, HTA is seen as providing a means of bridging sci-
entific evidence, the judgment of health professionals,
the views of patients and the general public, and the
needs of policymakers [3].
From a policy perspective, the potential value of eco-
nomic evaluation to public health policy decisions, par-
ticularly at the early stages of development, includes
supplementation of monitoring and assessment of innova-
tions in horizon scanning and HTA activities, the control
of technology diffusion by informing coverage and reim-
bursement decisions, and the direct public promotion of
healthcare technologies, leading to increased efficiency [4].
In line with this subscription to HTA methodology, there
has been an increase in demand for economic evidence
and its evaluation from purchasers and regulators.
In the UK, one of the outcomes of the Healthcare Indus-
tries Task Force initiative [5], comprising British govern-
ment, health professionals, and representatives from the
medical technology industry, was to bring health econom-
ics (HE) considerations into purchasing guidance by the
creation, in 2005, of the Centre for Evidence-based Pur-
chasing (CEP) out of the more technically oriented Device
Evaluation Service (DES). More recently the Medical
Technologies Evaluation Programme (MTEP) of the Na-
tional Institute of Health and Clinical Excellence (NICE)
has taken over the remit of CEP with the aim of helping
the National Health Service (NHS) in England and Wales
adopt efficient and cost-effective medical devices and diag-
nostics more rapidly and consistently [6]. This technology
evaluation programme demands that manufacturers pro-
vide their own evidence of economic value from existing
literature or from de novo economic models in addition to
the usual clinical evidence. The MTEP programme
requires at least a cost-consequences analysis to be con-
ducted where cost and clinical benefits are tabulated side
by side so that decision makers can make judgements
about costs associated with the benefits. However, cost-
effectiveness is explicitly absent from NICE’s existing
Interventional Procedures Programme where device-
related procedures have been typically submitted for
evaluation before the existence of the MTEP, so this is a
considerable change for manufacturers of medical devices.
Furthermore it has also meant changes for the evaluation
organisations involved, several of which have provided ser-
vices throughout the transition from DES to NICE.The NHS has also been striving to improve its level of
innovativeness through the efforts of the National
Innovation Centre, the National Technology Adoption
Centre and through programmes such as QIPP (Quality,
Innovation, Productivity and Prevention). This has
resulted in the widening of interest in HE amongst
healthcare organisations more generally. In the USA for
example, comparative effectiveness research focuses on
the generation and synthesis of clinical evidence to com-
pare the benefits and harms of alternative methods to
address a clinical condition or improve the delivery of
care. Its introduction and applicability to “real world”
settings raises the question of the need for wider under-
standing of HE methods for those who may wish to ar-
ticulate the cost impact of selected treatments on health
systems, and for companies that are providing products
associated with those treatments [7].
Whilst the demand for economic evaluation in medical
device development is growing, there has also been
thinking around how to integrate findings from HE work
into practice. It has been acknowledged that there are
outstanding problems around the incorporation of HE
methods into the medical device sector which has inhib-
ited the use of more established methods common in
the evaluation of pharmaceutical products. For example,
the nature of ongoing product modifications that are
experienced by devices during development means that
there is unlikely to be a ‘steady-state’ period where a de-
vice could be evaluated in a traditional setting such as a
randomised controlled trial [8]. Further to this, a new
therapy involving a device may have a wider financial
implication for a healthcare provider organisation that is
more difficult to forecast [9]. From the provider perspec-
tive, an interactive process in which clinical and eco-
nomic estimates are used alongside emerging evidence
from actual use has been highlighted as one means of
addressing the issue [10]. Even so, there is ongoing dis-
cussion about the construction of such estimates (e.g.
should the public or experts be consulted in the con-
struction and elicitation of quality of life estimates) [11].
These details may not be so much of a concern if com-
panies are able to apply “rough and ready” methods at
very early stages of development [12] and if assessors are
accommodating to such practices [13]. While research
explores the need to strengthen modelling for devices
and plans new ways to incorporate emerging evidence
into analyses [8], there is still a need to establish how
manufacturers and the medical device industry incorpor-
ate economic evaluations of new and existing products
to articulate their value to purchasers and regulators.
In the UK, the main government agency for funding
research and training in engineering and the physical
sciences, the Engineering and Physical Sciences Research
Council (EPSRC), is supporting multidisciplinary applied
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knowledge transfer of HE methods and tools to the
healthcare technologies industry. In a short, exploratory
study conducted by the authors, linked to a series of work-
shops for the medical device industry, participants com-
pleted a questionnaire to provide insight into the self-
reported levels of HE knowledge (in terms of assessing
whether procedural knowledge of health economics was
rated as high or low), strategies currently used by small
and medium-sized enterprises (SMEs) to assess and ar-
ticulate the value of new technology, and factors perceived
by SMEs to be of importance to purchasers in the context
of appraising technology. The insight sought from this re-
search is current practices of SMEs and how this can be
used to inform wider efforts in the education available to
industry. Whilst SMEs can draw on health economics
consultancy and other providers of such services, it is the
in-house practices that are examined in this paper.
Method
This research adopted an exploratory approach to inves-
tigate HE knowledge of participants attending work-
shops for the medical device sector on product
development, and identify factors that they perceived as
important to purchasers. This was achieved through the
analysis of participant responses to paper-based ques-
tionnaires that were administered following a workshop.
As one part of a university-led research programme in
evaluation methods and tools for medical device
innovation, the authors hosted a range of half-day work-
shop events, lasting around four hours each, between
2007 and 2011. The workshops were free to attend, and
were designed to introduce medical device manufac-
turers to tools for use in product development. The tools
included a user requirements guide to support user test-
ing and requirements gathering [14], and a spreadsheet
tool for early economic assessment of medical devices
[15], which were introduced and discussed within the
context of clinical case studies. Industry views about in-
volving users during development have been reported on
elsewhere [16].
In total, 12 workshops took place, provided to mem-
bers of industry networks, and trade associations. The
events were hosted by the Association of British
Healthcare Industries trade association, and four of the
regional industry network partnerships (Medilink East
Midlands, Medilink West Midlands, Yorkshire & Hum-
berside Medilink and the South East Health Technol-
ogy Alliance). The marketing for all events was focused
on attracting participants from SMEs and innovators
that were looking to focus on uptake of their products
by the NHS.
Due to resource and time constraints, data was gath-
ered at five of the workshops, which comprises the datapresented in this paper. Data was captured from work-
shops based in the East Midlands, Yorkshire and
Humber and South East of England, although partici-
pants who attended the workshops were based in com-
panies outside of the geographical boundaries. Data
from two workshops hosted by Medilink East Midlands
were included in this paper. The questionnaires were
provided to the participants at the end of the workshop
session, so that responses relating to HE knowledge
prior to the workshop could be informed following dis-
cussion of the topic. The questionnaires were adminis-
tered by a researcher not involved in the delivery of the
content for the workshop. The questionnaires outlined
that information provided was to be used for academic
research into the needs of industry and adopters of inno-
vations within the NHS, is confidential, and that
reported findings from the research will not refer to
named organisations.
The questionnaire contained six sections: i) description
of participants’ organisation and their role within it; ii)
self-rating of their procedural knowledge of HE prior to
the workshop (using 5-point scale from ‘none’ to ‘expert);
iii) participant identification of any formal decision-
making tools that are used within their organisation to
support product development (e.g., strategic and financial
valuation of projects, weighting and scoring of products
and product criteria) iv) participant rating of the import-
ance of six decision-making priorities when initiating med-
ical device development, using a 5-point scale from ‘very
important’ to ‘not important’ (anticipated profit margin,
market competition, enthusiasm of customer for a device,
purchasers opinion, expert opinion, uniqueness of the
technology); v) participant rating of how important they
thought each of seven factors were to purchasers when
assessing a product during procurement, using a 5-point
scale from ‘very important’ to ‘not important’ (device price,
cost effectiveness, expert opinion, patient group opinion,
safety of the product, company reputation, environmental
impact); vi) participants description of how they would
aim to demonstrate the value of medical products to the
NHS or other healthcare purchasers (e.g., clinical trial, key
opinion leaders, cost-effectiveness calculation); vii)
whether participants envisaged that a spreadsheet tool for
early economic assessment of medical devices could
be utilised by their company (responding with the
options ‘yes’, ‘maybe’, or ‘no’), and were asked to list
who would be likely to use it. The factors included in
questions around decision-making priorities and pur-
chaser decisions during procurement were generated
through discussions within the research team, draw-
ing on expertise in the development and purchasing
of medical devices. Qualitative data from participant
responses were analysed to reveal emerging themes,
presented as frequencies or indicative text. Where
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levels of HE knowledge as the independent variable.
Statistical analysis using non-parametric tests was
performed on questions with approximately interval
scales. Where statistical analysis was required for
responses, IBMW SPSSW software was used.
Results
Organisations and role of participants
Of the total number of participants who attended the
five workshops (N= 69), 62% were from SMEs (N= 43)
(see Table 1). The remaining participants were from
larger companies, universities or health providers.
Although all participants from SMEs completed a post-
event questionnaire, responses were not provided by
participants for all of the questions. The majority of
participants from SMEs held the role of managing dir-
ector or director in the company in which they were
based, with the role of director covering responsibilities
across a range of activities, including marketing, new
product development, and commercial roles.
Health economics knowledge
Of the participants from SMEs, 23% of respondents
reported having no, or almost no, knowledge of HE, 37%
reported a response of low HE knowledge, 33% medium,
5% high and 2% expert (Figure 1).
Use of formal decision-making tools within participant
companies
When asked to identify any formal decision-making
tools that are used within their organisation, 42% of
respondents (N = 40) said that they were using at least
one form of tool in their business. Amongst the
respondents, stage-gate methods, technology road-
maps and HE were mentioned as formal methods.
Other responses indicated the use of formal methods
without specifying them. Amid the reported HE
methods used, Monte Carlo sensitivity simulations (a
financial planning approach that analyses multipleTable 1 Breakdown of the job roles of workshop
participants attending the workshops
Job role Number (%)
Director 17 (39.5%)
Managing Director 16 (37.2%)
Manager 2 (4.7%)
Product Manager 2 (4.7%)
Senior Project Manager 1 (2.3%)
Company Secretary 1 (2.3%)
Senior Partner 1 (2.3%)
Consultant 1 (2.3%)
Not Defined 2 (4.7%)projections using a range of possible return rates),
basic HE models and use of Quality-adjusted Life
Years (QALY) (a metric that takes into account both
the quantity and quality of life generated by health-
care interventions and is the arithmetic product of
life expectancy and a measure of the quality of the
remaining life-years [17]) were highlighted. Quantita-
tive market research methods were also described as
formal by some respondents. Decision methods
described as informal by participants included prior
experience, boardroom decisions and decisions made
on criteria of market analysis/user demand and prac-
tical means of delivery, also including assessment of
intellectual property protection.
Table 2 shows that the use of formal decision-making
tools was greater for those participants reporting medium,
high, and expert HE knowledge, with greater proportions of
those reporting low to none HE knowledge also being non-
users of formal decision-making tools. The relationship be-
tween these variables was assessed, but no significant rela-
tionship was found (τ=−0.138, p≥0.05).
Decision-making priorities
When probing companies’ motivating factors for devel-
oping a new product using six factors (anticipated profit
margin, market competition, enthusiasm of the customer
for the device, purchaser opinion, expert opinion and
uniqueness and readiness of the product) a Friedman test
was used to analyse variance in the participant responses
(N= 32) by ranks. However, the analysis revealed no sig-
nificant differences in the ranking of these six factors
(χ2 (5) = 7.00, p ≥ 0.05).
Participant rating of factors perceived to be of
importance to purchasers
To examine the participants’ ratings of factors perceived
to be of importance to purchasers when assessing a
product during procurement (N= 39), responses were
ranked using the Friedman test which highlighted an
overall statistically significant difference between the0%
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Figure 1 Knowledge of health economics amongst workshop
participants (N= 43).
Table 2 Knowledge of Health Economics vs. Use of
Formal Decision-Making Tools
Knowledge of
Health Economic
Use of Formal
Decision Making
Tools (N= 40)
Yes No
None 4 (44%) 5 (56%)
Low 4 (27%) 11 (73%)
Medium 7 (54%) 6 (46%)
High 1 (50%) 1 (50%)
Expert 1 (100%) 0 (0%)
Table 4 Methods currently used by delegates to
demonstrate value to purchasers
Methods used for demonstrating value Number of delegates
Clinical trials (external and internal) 11
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p < 0.05). Table 3 displays the average ranks of the differ-
ent categories according to their perceived importance
to purchasers.
From these tests we were able to rank the six factors.
Safety of the product, Expert opinion, Cost-effectiveness
and Device price were found to be similarly ranked
(mean rank between 2.89 and 3.32) with no statistical
difference between these factors. This was followed by
Company/brand reputation and Patient group opinion
which were both ranked significantly lower than all of
the top four factors, but not significantly different from
each other (ranking 4.51 and 5.32 respectively). Lastly,
Environmental impact had the lowest rank that was sig-
nificantly lower than all other factors (mean rank 5.85).
Participants’ description of how they aim to demonstrate
the value of medical products to the NHS or other
healthcare purchasers
Workshop participants were asked to put in words how
they would demonstrate value to purchasers. Table 4
documents explicit mention of methods used by the par-
ticipants (N = 43), which were accompanied by more
general references to evidence-based medicine, cost-
benefit analysis to healthcare providers and patients, and
statement of benefits. The responses documented in
Table 4 were coded from qualitative responses, with a
varied number of responses provided by individual
participants.Table 3 Factors of importance to purchasers, as rated by
the workshop participants
Category Rank
Safety of the Product 2.89
Expert Opinion 2.97
Cost Effectiveness 3.12
Device Price 3.32
Company/Brand Reputation 4.51
Patient Group Opinion 5.32
Environmental Impact of a Product 5.85To provide more insight into the descriptions provided
by participants about how their company aims to dem-
onstrate the value of medical products to purchasers,
Table 5 outlines the exact responses of a selection of
participants.
It is apparent from reviewing the comments that there
is diversity in the approaches applied by SMEs and no
clear consensus was evident in the reporting of methods
used to demonstrate the value of their medical products
is present.
The last question on the questionnaire asked partici-
pants whether they would consider using a HE spread-
sheet tool in their company and who would be likely to
use it. From the responses gathered (N= 39), 67% of par-
ticipants indicated that they would be likely to use such
a tool, 26% stated maybe, and 7% said that they would
not use such a tool. For those participants who identified
that they would be likely to use such a tool, it was high-
lighted that there would be scope to apply the tool in re-
search and development teams, marketing and sales
departments, or both within their companies.
Discussion
Amongst participants from SMEs attending training
workshops tools for use in product development, HE
was perceived as of importance to purchasers, and is
entering into decision-making processes by SMEs in the
medical devices industry. Prior knowledge of HE was
such that 2 in 5 of the participants already had at least
medium knowledge. Cost-effectiveness was ranked by
SMEs to be amongst the top factors influencing purcha-
sers, and 92% of respondents said that their company
would use or might use a HE tool. At the same time, less
than half of the companies reported using formal meth-
ods of decision support during product development. In
terms of demonstrating the value of a product, clinicalCost analysis and cost-effectiveness studies 10
Outcomes Survey 4
Demonstrate public and patient benefit 4
Comparative studies 2
Demonstrate benefits to user 2
Opinion leader support 2
All factors listed in the questionnaire 2
Demonstrate product quality 1
Demonstrate benefit to healthcare provider 1
Peer-review publications 1
Seminars / demonstrations 1
Table 5 Participant responses about how their company aims to demonstrate the value of medical products to
purchasers
Statement Role in company HE knowledge
“Comparative studies by experts” Director Low
“. . .through products effectiveness, values,
and how it can help improve users and patients life”
Product Manager Low
“Show the data on public health impact” Consultant Low
“Seminars, demos” Director Medium
“By demonstrating product quality” Senior Partner Medium
“Business model based on PSSRU figures,
clinical benefits, peers review formal publications”
Director High
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alongside cost-effectiveness which was mentioned by al-
most 1 in 6 participants in those applying formal
methods.
The findings of this paper suggest that, for those parti-
cipants from SMEs who attended the workshops, there
is an awareness of the increasing use of HE by purcha-
sers in decision making. However, the varying levels of
HE knowledge reported by participants from SMEs, and
the lack of HE in decision making during product devel-
opment suggests that attention may need to be given to
education needs, and tools to support the application of
HE. There is currently no research that examines the
most effective means of educating those from industry
about HE and the wider coverage of HTA, so this is also
an area for future research.
Taking a global perspective in their report on HTA of
medical devices, the World Health Organisation [18]
outline that disseminating knowledge and skills in HTA
should be based on a progressive strategy. The sug-
gested first stage is the identification of individuals with
a capacity for accessing and understanding HTAs, and
then making these individuals the “focal points” of HTA
and scientific evidence of effectiveness of healthcare
interventions. The “focal points” could be located in a
national research organisation, government, a university
or other non-profit agencies concerned with advancing
the use of HTA for good governance in policy and deci-
sion making. Their role would be to facilitate and mo-
bilise knowledge around HTA, using such methods as
organising or facilitating meetings, providing presenta-
tions and conducting workshops. The WHO report
draws on research from Romania [19] in which it is
pointed out that success in implementing a HTA pres-
ence in a country setting depends on factors such as
local political, economic, and educational support. The
multidisciplinary and interdisciplinary nature of HTA
sees HE amidst its array of components and, as such,
how it is taught to and used by manufacturers feeds into
the wider implementation of HTA. With well-
established HTA bodies in the UK, it is a useful testingground to understand how best manufacturers and
developers of medical technology can adopt and imple-
ment HE within an environment in which there are in-
creasing calls for its use. The progressive strategy
outlined by the WHO may provide an opportunity to
assess the agenda for increasing knowledge around HE
within the context of HTA, alongside providing under-
standing on how best to disseminate knowledge to sup-
port HTA development more widely.
In the UK, processes such as the NICE Medical Tech-
nologies Evaluation Programme do now require the for-
malised use of economic evaluation methods such that
submissions by industry are expected to perform at least
a cost-consequences analysis. Although process and
methods guides are provided for those submitting tech-
nologies to this programme, the indication in this re-
search that some companies would use a spreadsheet
tool for early economic evaluation, in particular those
who see scope for its use in research and development,
indicates that there may be scope for policy makers to
engage with industry through the generation of spread-
sheet tools, such as those that are generated by NICE as
costing templates as part of implementation support.
Whilst this research has generated an initial insight
into the knowledge and awareness of HE use within
HTA for the medical device sector, it is acknowledged
that the sample size was inadequate to extrapolate out
to represent SMEs throughout the whole UK medical
device sector. Further research is required to identify the
extent of HE knowledge within SMEs and to develop
methods to support the education and implementation
of HE within the HTA landscape for medical devices in
the UK. As a starting point, research has shown that
those developing innovative medical devices struggle to
express the value of their work because they only engage
with HE at the later stages of development [20].
Any strategy around improving knowledge of HE
within the medical device industry should act on re-
search showing the benefits of its inclusion at the early
stages of development [21]. Although there is little re-
search on the education of the medical device industry,
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from developing collaborations between basic and clin-
ical researchers from academic institutions on the one
hand, with engineers and scientists from the research
divisions of device and pharmaceutical companies on
the other. Such links have been encouraged by the
European Society of Cardiology [22] as a way of devising
legitimate and ethical collaborations between healthcare
providers, academic institutions, professional associa-
tions, charitable foundations, and industry to support
continuing medical education and facilitate some of the
best and most innovative research ideas. However, indi-
cative of the ever-increasing range of stakeholders
involved in health research, there is need for closer
examination of diverse groups involved in this process
to understand the best way to meet their various needs.
This study points to the need for sustained effort in
education of HE so that its principles, and the benefits it
can deliver, are at the finger-tips of industry when they
are preparing their evidence. This would allow contin-
ued impact of cost-effectiveness in its position of sup-
porting healthcare decision makers, particularly in terms
of its role for informing technical issues around clinical
policies [23]. Whilst there have been guidelines devel-
oped for performing health economic evaluations
[24,25], their contribution to decision-making is through
definition of a minimum methodology to be applied
when forming or reviewing an economic evaluation. Al-
though this provides support to align expectations of
SMEs and healthcare providers regarding the construc-
tion of economic evaluations, the process of deciding
whether to adopt an innovation is not prescribed. A
similar issue extends out more widely into HTA, where
the structures, processes and mechanisms by which
technology coverage decisions can and should be made
in healthcare have also been highlighted as requiring fur-
ther research [26]. For HE, there is scope to explore pro-
viders’ decision making, and particularly to gauge the
importance of economic evaluation within this, which
could in turn impact on the uptake, construction, and
presentation of health economic evaluations by SMEs.
The participants discussed in this paper had attended
a workshop hosted by those conducting the research
which aimed to provide information on both health eco-
nomics and user needs. Whilst it is acknowledged that
the sampling strategy may have impacted the research
through a selection bias, the researchers emphasised
confidentiality to participants and, given the scarcity of
published industry views in this area, were keen to use
the collection of workshops as a means of interacting
with industry for this research. Additionally, an interest
in HE may have been a cause for participants to register
for the workshop, and the training provided in HE dur-
ing the workshop may have helped participants realiseits importance. Future research could consider alterna-
tive approaches to access SMEs, either through targeted
interviews or a broad survey of trade association mem-
berships. There is scope for more research in the area to
document the extent of need for HE education in indus-
try, through both increasing the sample sizes involved,
and by generating comparisons with other company
types within the medical device sector.Conclusion
This study points to the need for further research into
the education requirements of SMEs in the area of
Health Technology Assessment and also for investigation
into how SMEs engage with existing HTA processes as
required by assessors such as NICE. Furthermore, tools
to support economic evaluation are of interest to the
medical devices industry. It is hoped that the findings
presented will generate support in bridging the gap be-
tween increasing demands for health economics evi-
dence by policy makers and the delivery of responsive
information and self-evaluation of cost-effectiveness of
products by SMEs in the medical device sector.
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